Results 121 to 130 of about 15,465 (199)
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Rheumatoid arthritis (RA) requires lifelong treatment with disease‐modifying antirheumatic drugs (DMARDs). In patients with sustained disease control, DMARD de‐escalation has been proposed to lessen treatment burden, but its efficacy and safety remain elusive.
Xiaoyan Zhang +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9346-9355, October 2026.ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg +10 more
wiley +1 more source
European Journal of Haematology, Volume 117, Issue 4, Page 922-935, October 2026.ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio +38 more
wiley +1 more source
Journal of Dermatological TreatmentBackground Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and ...
Andreas Wollenberg +9 more
doaj +1 more source
International Journal of Dermatology, Volume 65, Issue 10, Page 2091-2101, October 2026.A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair +17 more
wiley +1 more source
, 2021 Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA).
Riva, Marta +23 more
core
Large‐scale meta‐analysis of infection risk with JAK–STAT inhibitors in 29,000 patients
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1662-1674, October 2026.In this large meta‐analysis of 74 randomized controlled trials involving more than 29,000 patients, JAK–STAT inhibitors were associated with an increased risk of influenza, bronchitis and herpes infections, particularly herpes zoster, while an increased risk of serious opportunistic or fungal infections was not observed.
Máté Krebs +10 more
wiley +1 more source
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn +17 more
wiley +1 more source
OBJECTIVE The Baricitinib in New-Onset Type 1 Diabetes (BANDIT) trial showed that baricitinib treatment for 48 weeks preserved β-cell function and lowered insulin requirements and glucose in recent-onset type 1 ...
Jessica E. Harbison +56 more
core +1 more source
Demographic information of 10 LV patients treated with baricitinib
Baseline data of 10 patients with LV who were treated with ...
Wei, Dandan
core +1 more source